Opioid addiction, treatments

The management of comorbid medical and psychiatric conditions has become an essential component of effective opioid addiction treatment. Hepatitis C has now surpassed AIDS as the most common cause of death in... 

Stock, C. and J.H. Shum, Bupreorphine a new pharmacotherapy for opioid addictions treatment, J. Pain Palliat. Cate Pharmacother., 18(3), 35-54, 2004. 

Alcohol, Naltrexone is a p-opioid receptor antagonist first synthesized in the opioid 1960s. Naltrexone was approved by the FDA for the treatment of opioid addiction treatment in 1984 and alcohol addiction in 1994 [247]. Naltrexone blocks the euphoric effects of opioids by binding competitively to opioid receptors, but does little to curb craving for opioids. Because naltrexone is an opioid antagonist there is little risk of abuse or dependence given that it does not have intrinsic opiate effects and therefore is not reinforcing [248]. 

Administration (FDA) for the treatment of opioid addiction. Treatment is initiated with buprenorphine alone administered sublingually, followed by maintenance therapy with a combination of buprenorphine and naloxone (Suboxone) to minimize abuse potential. The partial agonist properties of buprenorphine limit its usefulness for the treatment of addicts who require high maintenance doses of opioids. However, conversion to maintenance treatment with higher doses of methadone, a full agonist, is possible. 

Opioid addiction treatment Dispensing of approved medication to prevent withdrawal and craving during elimination of opioid use by a patient in medication-assisted treatment (MAT), with or without a comprehensive range of medical and rehabilitative services or medication prescribed when necessary to alleviate the adverse medical, psychological, or physical effects. 

Opioid addiction treatment pharmacotherapy is appropriate for persons who are currently addicted to an opioid and became addicted at least 1 year before admission to the program. Physicians can make exceptions to the 1-year rule if patients were recently released from prison, patients are pregnant, or patients were previously treated up to 2 years after discharge. 

What is the recommended period of time of documented addiction required prior to placement in an opioid addiction treatment program ... 

Patients being treated with naltrexone should abstain from all long-acting opioids for what period of time before beginning opioid addiction treatment ... 

Dennis BB, Bawor M, Paul J et al (2015) The impact of chronic pain on opioid addiction treatment a systematic review protocol. Syst Rev 4 49... 

---